19
Participants
Start Date
January 31, 2008
Primary Completion Date
December 31, 2011
Study Completion Date
December 31, 2011
CS-7017
At Phase 1, CS-7017 will be tested in combination with paclitaxel at the following dosage levels: 0.15, 0.30, or 0.50 mg BID. At Phase 2, CS-7017 will be administered at the recommended phase 2 dose (RP2D).
Paclitaxel
Commercially available paclitaxel will be administrated as IV infusion over 3 hours once every 3 weeks.
University of Pennsylvania Maloney Hospital, Philadelphia
Eastern Virginia Medical School, Norfolk
Mayo Clinic, Jacksonville
Vanderbilt Ingram Cancer Center, Nashville
Ohio State Univ, Columbus
Mayo Clinic, Rochester
Washington University, Siteman Cancer Center, St Louis
Univ of Colorado Cancer Center, Aurora
Oregon Health Science Univ, Portland
Massachusetts General Hospital, Boston
Lead Sponsor
Daiichi Sankyo
INDUSTRY